TY - JOUR
T1 - COX-2 induces T cell accumulation and IFN-γ production during the development of chromium allergy
AU - Sitalaksmi, Ratri Maya
AU - Ito, Koyu
AU - Ogasawara, Kouetsu
AU - Suto, Yoshiko
AU - Itabashi, Madoka
AU - Ueda, Kyosuke
AU - Hirasawa, Noriyasu
AU - Narushima, Takayuki
AU - Hendrijantini, Nike
AU - Kresnoadi, Utari
AU - Sasaki, Keiichi
PY - 2019/8/18
Y1 - 2019/8/18
N2 - Chromium (Cr) is commonly added into various metal alloys to improve some mechanical properties such as corrosion resistance, strength, and workability. However, Cr is also known to be a metal allergen for some individuals. Metal allergy is a T cell-mediated disease with symptoms of inflammation and swelling that involve inflammatory cytokines and prostaglandins. Hence, suppressing these inflammation paths by using COX-2 inhibitor might be useful in treating Cr allergy. In this study, mice were used with Cr-induced allergy challenge model. The mice were injected with celecoxib once per day for 7 days one hour after the challenge. Footpad samples were stained with haematoxylin and eosin (H&E), and lymphocytes were isolated from popliteal lymph nodes for the flow cytometric analysis. The results show that both prostaglandin E2 (PGE2), a known mediator of inflammation, and cyclooxygenases (COX)-2 have important roles in the development of Cr allergy. Further, COX-2 inhibitor, celecoxib, was effective in relieving swelling and inflammation in Cr-allergic mice concordant with suppression of IFN-γ production by CD8+ T cells and T cell accumulation in the lymph nodes. Therefore, the inhibition of COX-2 may be a therapeutic target for Cr allergy, and additional molecules in the PGE2 signalling pathway may also be an effective therapeutic target for the treatment of metal allergy.
AB - Chromium (Cr) is commonly added into various metal alloys to improve some mechanical properties such as corrosion resistance, strength, and workability. However, Cr is also known to be a metal allergen for some individuals. Metal allergy is a T cell-mediated disease with symptoms of inflammation and swelling that involve inflammatory cytokines and prostaglandins. Hence, suppressing these inflammation paths by using COX-2 inhibitor might be useful in treating Cr allergy. In this study, mice were used with Cr-induced allergy challenge model. The mice were injected with celecoxib once per day for 7 days one hour after the challenge. Footpad samples were stained with haematoxylin and eosin (H&E), and lymphocytes were isolated from popliteal lymph nodes for the flow cytometric analysis. The results show that both prostaglandin E2 (PGE2), a known mediator of inflammation, and cyclooxygenases (COX)-2 have important roles in the development of Cr allergy. Further, COX-2 inhibitor, celecoxib, was effective in relieving swelling and inflammation in Cr-allergic mice concordant with suppression of IFN-γ production by CD8+ T cells and T cell accumulation in the lymph nodes. Therefore, the inhibition of COX-2 may be a therapeutic target for Cr allergy, and additional molecules in the PGE2 signalling pathway may also be an effective therapeutic target for the treatment of metal allergy.
KW - COX-2
KW - Metal allergy
KW - celecoxib
KW - chromium
KW - inflammation
UR - http://www.scopus.com/inward/record.url?scp=85074262704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074262704&partnerID=8YFLogxK
U2 - 10.1080/08916934.2019.1662404
DO - 10.1080/08916934.2019.1662404
M3 - Article
C2 - 31587584
AN - SCOPUS:85074262704
VL - 52
SP - 228
EP - 234
JO - Autoimmunity
JF - Autoimmunity
SN - 0891-6934
IS - 5-6
ER -